Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5941
    -0.0008 (-0.14%)
     
  • NZD/EUR

    0.5549
    +0.0009 (+0.16%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    94.0360
    +1.5400 (+1.66%)
     

E*TRADE Rallies 10.5% Quarter to Date: What's Driving It?

Zacks.com featured highlights include: Twitter, Lockheed Martin, Intercontinental Exchange, CBRE and Keurig Dr Pepper

During the Q1 earnings season, financial stocks put up a decent show. Notably, one such investment bank — E*TRADE Financial Corporation ETFC — has rallied 10.5% quarter to date, significantly outperforming the industry’s decline of nearly 6%.

This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business. Furthermore, anticipated improvement in trading activities and several of the company’s ongoing initiatives bode well for E*TRADE.

This apart, E*TRADE is part of the industry, which has a Zacks Industry Rank #64 (top 25%).



Moreover, the stock seems undervalued on the basis of its PEG and price-to-book (P/B) ratios. E*TRADE has a PEG ratio of 1.03 compared with the S&P 500 average of 1.77. Also, the company’s P/B ratio of 2.67 is below the S&P 500 average of 3.17.

Additionally, estimates for this Zacks Rank #3 (Hold) stock have been on an upswing. Over the last 60 days, the Zacks Consensus Estimate has moved up slightly for 2018 and 1.2% for 2019.

Fundamentally, E*TRADE’s earnings have jumped 30.32% annually over the last three to five years. The earnings growth momentum is anticipated to continue in the near term as well. The company’s projected EPS (earnings per share) growth (F1/F0) is 66.21% for 2018 and (F2/F1) around 12.24% for 2019.

In the last three years (2015-2017), the company has recorded a benefit to provision for loan losses, with the trend continuing into first-quarter 2018 as well. We believe this benefit is driven by the company’s efforts to shrink its balance sheet.

Further, with a rise in rates, brokerage firms are likely to engage in more investment activities. As brokerage firms earn interest income on un-invested cash in customer accounts, the rate hikes will enable these firms to invest at higher rates. As E*TRADE currently derives nearly 60% of its total net revenues from net interest income, the company is poised to benefit from the recent rate hikes.

Additionally, E*TRADE is focused on derivatives mix, with a target of increasing it to 35% of daily average revenue trades and also set managed account assets under management target of $6 billion within the next two years. The company aims to achieve 2-3% improvement in its rate of annual organic growth, across accounts, assets and trades.
 

Stocks to Consider

A few better-ranked stocks in the same space include LPL Financial Holdings Inc. LPLA, Evercore Inc EVR and Stifel Financial Corporation SF. LPL Financial and Evercore carry a Zacks Rank #1 (Strong Buy), while Stifel Financial holds a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

LPL Financial’s earnings estimates have been revised around 22.4% upward for 2018, in the past 60 days. Also, its share price has rallied 14.1% in six months’ time.

Evercore’s earnings estimates for 2018 have been revised 2.7% upward, over the last 60 days. Further, in the past six months, the company’s shares have jumped 18.5%.

Stifel Financial witnessed 1% upward earnings estimates revision for the current year, in the past two months. Moreover, over the past year, its shares have gained 16.4%.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
E*TRADE Financial Corporation (ETFC) : Free Stock Analysis Report
 
Stifel Financial Corporation (SF) : Free Stock Analysis Report
 
Evercore Inc (EVR) : Free Stock Analysis Report
 
LPL Financial Holdings Inc. (LPLA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.